Last10K.com

Nascent Biotech Inc. (NBIO) SEC Filing S-1 IPO Report

SEC Filings

NBIO Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

NBIO Annual Reports

NBIO Quarterly Reports

NBIO Corporate News

NBIO Registration of Securities

  • S-1 Registration of Securities March 2024
    • S-1 Registration of Securities September 2022
    S-1 Registration of Securities December 2020

Nascent Biotech Inc.

HISTORY TOOLS
CIK: 1622057 Ticker: NBIO

View differences made from one to another to evaluate Nascent Biotech Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this S-1 Registration of Securities to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nascent Biotech Inc..

Continue

Assess how Nascent Biotech Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nascent Biotech Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this S-1 Registration of Securities

Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Consolidated Statements Of Stockholders Deficit (Unaudited)
Basis Of Presentation
Basis Of Presentation (Policies)
Basis Of Presentation (Tables)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Convertible Debt
Convertible Debt (Details Narrative)
Equity
Equity (Details Narrative)
Fair Value Measurements And Derivative Liabilities
Fair Value Measurements And Derivative Liabilities (Details)
Fair Value Measurements And Derivative Liabilities (Tables)
Going Concern
Going Concern (Details Narrative)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Details)
Income Taxes (Tables)
License Agreement
License Agreement (Details Narrative)
License Settlement
License Settlement (Details Narrative)
Options
Options (Details Narrative)
Options (Details)
Options (Tables)
Organization And Nature Of Operations
Organization And Nature Of Operations (Details Narrative)
Related Party Transactions
Related Party Transactions (Details 1)
Related Party Transactions (Details 2)
Related Party Transactions (Details Narrative)
Related Party Transactions (Details)
Related Party Transactions (Tables)
Significant Accounting Policies (Details Narrative)
Significant Accounting Policies (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Warrants
Warrants (Details Narrative)
Warrants (Details)
Warrants (Tables)

Material Contracts, Statements, Certifications & more

Nascent Biotech Inc. provided additional information to their SEC Filing as exhibits

Exhibit 5.1: Opinion
Exhibit 23.1: Consent Of Fruci &Amp; Associates Ii, Pllc
Exhibit FILING FEES: Filing Fee Table
Ticker: NBIO
CIK: 1622057
Form Type: S-1 Registration of Securities
Accession Number: 0001477932-24-001231
Submitted to the SEC: Thu Mar 14 2024 9:14:55 PM EST
Accepted by the SEC: Fri Mar 15 2024
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/nbio/0001477932-24-001231.htm